BACKGROUND
Along with adequate surgical resection, adjuvant chemotherapy has played an important role in improving the survival for patients with colon cancer, and current guidelines recommend the use of adjuvant chemotherapy for patients with surgically resected stage III or IV colon cancer. 1 Systemic chemotherapy is also used in the neoadjuvant setting for patients with metastatic or locally invasive disease that may become surgically resectable. The role of adjuvant therapy in earlier-stage tumors with certain high-risk features is an area of active investigation. The Table summarizes the important trials that have influenced adjuvant chemotherapy for colon cancer.
Oxaliplatin-based adjuvant chemotherapy is standard of care for stage III disease based on multiple clinical trials. [2] [3] [4] [5] The Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer 2 compared adjuvant chemotherapy regimens of bolus plus continuous-infusion fluorouracil (5-FU) plus leucovorin (LV) with or without the addition of oxaliplatin for resected stage II or III colon cancer. Patients in the oxaliplatin group (5-FU and oxaliplatin (FOLFOX)) had a higher rate of 5-year diseasefree survival (73% vs 67%), and FOLFOX has become the standard of care for adjuvant chemotherapy. A 10-year follow-up report showed that the FOLFOX regimen was associated with a significantly higher rate of overall survival for stage II/III patients (72% vs 67%), most notably in stage III patients (67% vs 59%). 3 The National Surgical Adjuvant Breast and Bowel Project C-07 trial demonstrated a benefit for bolus fluorouracil plus leucovorin and oxaliplatin (FLOX), 4 and the capecitabine-based regimen (CAPEOX) has also shown a survival benefit, 5 but both are associated with higher toxicity. At this time, FOLFOX is the preferred regimen for stage III colon cancer, whereas FLOX and CAPEOX are reserved as alternatives if infusional therapy is not feasible.
Trials have also investigated other agents for adjuvant chemotherapy in stage III colon cancer without success. The Cancer and Leukemia Group B 89803 study 6 compared adjuvant 5-FU and LV with and without irinotecan and found no difference in survival, with potentially worse adverse effects in the irinotecan group. The Bevacizumab Plus Oxaliplatin-Based Chemotherapy as Adjuvant Treatment for Colon Cance r7 study investigated FOLFOX or CAPEOX with and without bevacizumab (Avastin) and found no benefit and potential harm with the addition of bevacizumab to adjuvant treatment regimens. As such, adjuvant treatment at this time is based on FOLFOX without the addition of other agents.
The role of adjuvant chemotherapy for stage II colon cancer is less clear. The International Multicentre Pooled Analysis of B2 Colon Cancer Trials 8 pooled data from 5 trials and found no survival benefit for adjuvant therapy in stage II disease, although adjuvant chemotherapy in these studies was 5-FU plus LV, without oxaliplatin or other agents. The Quick and Simple and Reliable study randomly assigned patients with colorectal cancer and an "uncertain indication for adjuvant chemotherapy" to receive either no adjuvant chemotherapy or adjuvant therapy including 5-FU and LV with or without levamisole depending on the timing of randomization. 9 The benefit of adjuvant chemotherapy in patients with stage II cancer was borderline significant, whereas the benefit for patients with stage III cancer was not significant. Therefore, the results of this study must be interpreted with caution. No benefit, and possible harm, with adjuvant Avastin Ava = Avastin (bevacizumab); DFS = disease-free survival; DSS = disease-specific survival; FLOX = bolus fluorouracil (5-FU) + leucovorin + oxaliplatin; FOLFOX = 5-FU + leucovorin + oxaliplatin; Iri = irinotecan; IV = intravenous; Lev = levamisole; LV = leucovorin; MOF = lomustine, vincristine, and 5-FU; OS = overall survival; Ox = oxaliplatin; RR = relative risk; XELOX = capecitabine + oxaliplatin. *To access the hyperlinks to the PubMed abstracts for each study, go to https://tinyurl.com/y8lcsuzc.
PRESENTATION AND DIAGNOSIS
Most patients with colon cancer are identified by either screening colonoscopy or after a patient presents with anemia, weight loss, or other symptoms. The entire colon must be visualized to identify synchronous lesions. Workup should include a complete blood count, a basic metabolic panel, carcinoembryonic antigen, and CT of the chest, abdomen, and pelvis. The TNM classification system developed by the American Joint Committee on Cancer 1 is used for staging. Stage I disease is localized to the colon and is associated with a 92% rate of 5-year overall survival. Stage II disease is more locally invasive, with survival rates of 87% and 63% for stages IIA and IIB. Stage III disease involves regional lymph nodes and is associated with 5-year survival rates of 89%, 69%, and 53% for stages IIIA, IIIB, and IIIC. Stage IV represents metastatic disease and has been associated with a survival rate of 11%, although recent advances in treatment are prolonging survival for many patients.
10
MANAGEMENT An algorithm for the management of colon cancer can be found in the section on Evaluation and Treatment Algorithm. This is based on the current National Comprehensive Cancer Network guidelines for management of colon cancer and highlights the role of systemic chemotherapy for these patients.
Adjuvant chemotherapy is not indicated for resected stage I colon cancer with negative margins and is not the standard of care for stage II disease. Both the National Comprehensive Cancer Network and the American Society of Clinical Oncology advocate a detailed risk/benefit conversation with stage II patients regarding adjuvant chemotherapy. Published studies including heterogeneous populations of patients with stage II colon cancer have not shown improved survival with adjuvant chemotherapy, but new data are emerging regarding the benefit for tumors with certain high-risk features. 1 Microsatellite instability is a specific tumor characteristic that may be helpful in evaluating patients with stage II cancer for adjuvant therapy. 1 Patients with high microsatellite instability (MSI) have been shown to have a better prognosis than patients with low MSI, which may have an increased likelihood to metastasize. Moreover, studies have suggested that patients with high MSI tumors may not benefit from adjuvant chemotherapy, whereas patients with low MSI tumors do. As such, all resected colon cancers should undergo MSI testing to inform prognosis and guide treatment decisions.
Medically fit patients with stage III cancer should be referred to medical oncology after surgical recovery for consideration of systemic adjuvant chemotherapy to improve survival based on the results of the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer and other trials. Systemic therapy for stage IV disease is generally aimed at palliation and prolonging survival, with rare evidence of cure. Nevertheless, patients with metastatic disease who receive multimodal systemic therapy have greatly improved survival compared with supportive management alone. This is also because of more frequent use of surgery and other interventional therapies in the setting of metastatic disease. The available regimens include combinations of FOLFOX, FLOX, or CAPEOX with irinotecan, cetuximab, and bevacizumab. Chemotherapy in this setting should be individualized and determined with a coordinated multidisciplinary team.
There are also ongoing trials investigating the role of immunotherapy for patients with stage III or IV cancer in the adjuvant and palliative setting. The ATOMIC Trial (NCT02912559) 11 is currently enrolling patients with stage III colon cancer and deficient DNA mismatch repair to receive adjuvant therapy with FOLFOX with or without atezolizumab, a monoclonal antibody against the protein programmed cell death ligand 1. Similar antibodies are being investigated for multiple malignancies and are showing promise. Results of this trial and others may further revolutionize the treatment of colon cancer.
These adjuvant therapies are of course not given without adverse effects. Most commonly, these regimens can result in hair loss, mouth sores, GI issues, and fatigue. Oxaliplatin is known for causing a neuropathy that manifests as numbness, tingling, or pain in the hands and feet. It can also cause intense sensitivity to hot and cold in other parts of the body. These effects have been seen in <12% of patients a year after treatment. 3 Symptomatic management is the best available treatment at this time. 
